BLASUBCUTANEOUSINJECTABLE
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Clinical Trials (5)
Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)
Started Aug 2023
100 enrolled
Osteoporosis in Postmenopausal Women
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
Started Aug 2023
36 enrolled
Giant Cell Tumor of Bone
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
Started Feb 2023
300 enrolled
BRCA1 MutationBreast CancerBreast Diseases+3 more
A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®
Started Jul 2022
504 enrolled
Postmenopausal Osteoporosis
Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers
Started Jan 2022
207 enrolled
Healthy Male Subjects